about
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelSwitching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.[Rheumatoid arthritis].Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Can biosimilars help achieve the goals of US health care reform?Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Sirukumab: a promising therapy for rheumatoid arthritis.Biosimilars and the extrapolation of indications for inflammatory conditions.The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Update on biosimilars in rheumatology.Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).Drug tendering: drug supply and shortage implications for the uptake of biosimilarsCurrent perspective on rituximab in rheumatic diseases.Tocilizumab: A Review in Rheumatoid Arthritis.Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.Policies for biosimilar uptake in Europe: An overview.Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.Clinical trials of biosimilars should become more similar.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
P2860
Q28073310-E5941D90-EAAC-4621-977D-20F4666C23D0Q28078423-7E1FCFA2-E72E-46FB-8C3B-4F828019A52EQ30399745-CF44EE8D-0213-4DF5-A9F2-21863B600894Q33740641-D8C83C43-12C5-456A-98F0-B883E969DB65Q33840949-86747D34-3DE3-49F1-9602-415457E2CBADQ36241682-A3DA6A91-EF1B-44B6-823D-86E8F4336217Q38645738-9AA0E980-60DD-4E08-A4FB-DF35664878B5Q38670950-78C32947-B65D-477D-89FD-A716398AF442Q38708927-37CF8B33-F688-474D-9ECF-FCCC46C88864Q38856800-39CBA99C-650C-49B5-A600-DC0342818FA7Q38932150-D05CD00A-36FC-43F3-9316-C83DC39EDDB3Q38992643-E9A049AE-A929-465A-B2CB-2E0971460132Q39164941-BD7B1B43-3C51-4578-A0DE-E88452CB7B4CQ39260479-88517226-4CB6-40DC-8C3E-C2C0A325DFB0Q42113781-711D7A80-2D3B-45E5-BF15-7F6BE57D04F9Q42370596-3D06D0A3-3F27-4BEF-89DE-2A3B7916BAE8Q42373160-BCB494F2-1404-4E13-B72A-826525DF416CQ43280791-E5C8DE55-5DFD-4539-B230-3300DD014583Q47106974-2CBCAD08-D449-4921-823F-A8F42612FC08Q47173303-83A590C0-11AB-4B92-A315-0FBA8BF66860Q47633961-083C25AA-F5DA-4544-9B81-26FBFBDC4AFBQ47667333-4315CA0C-5A39-41D1-BA3A-DD324B3B851BQ47688424-7A974437-C40D-44E9-8C04-A696CAFC9ED8Q47731175-DFFE015D-0742-4726-A630-81DFD16A8FD4Q47807650-8D782E20-DD1A-4AED-895F-4F674DB2B647Q47836056-DC3487C5-F21B-47A1-AC97-298D520B8063Q47918450-5A381D49-704D-496C-BD9E-C07D608C2759Q47950956-103649BF-9446-4C7B-B3CF-BBC0900FB202Q48092147-40BD71CA-2DC5-40B9-9CD5-B8CA5C29EE4CQ49979586-4CF759C1-4A91-4FE9-BA52-BDCC4F7110EBQ50079741-545AE92F-D719-4B1A-A71F-3D90A5F64144Q50108062-F52D7FCD-FC15-43B1-9C19-7605DD109182Q57191804-663AB30D-6505-4D29-B93D-5FA0F8D7BDF9
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
The changing landscape of biosimilars in rheumatology
@ast
The changing landscape of biosimilars in rheumatology
@en
The changing landscape of biosimilars in rheumatology
@nl
type
label
The changing landscape of biosimilars in rheumatology
@ast
The changing landscape of biosimilars in rheumatology
@en
The changing landscape of biosimilars in rheumatology
@nl
prefLabel
The changing landscape of biosimilars in rheumatology
@ast
The changing landscape of biosimilars in rheumatology
@en
The changing landscape of biosimilars in rheumatology
@nl
P2093
P2860
P50
P921
P1476
The changing landscape of biosimilars in rheumatology
@en
P2093
João Gonçalves
László Gulácsi
Paul Cornes
Thomas Dörner
Vibeke Strand
Yoshiya Tanaka
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-209166
P407
P577
2016-06-01T00:00:00Z